Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | HRH2 | P25021 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27268679 | 1.00 | SIGMAR1 (0.62) | SIGMAR1HRH2LMNADRD4 | |
| SCHEMBL27166282 | 1.00 | SIGMAR1 (0.62) | SIGMAR1HRH2LMNADRD4 | |
| SCHEMBL27166245 | 0.93 | SIGMAR1 (0.61) | SIGMAR1HRH2LMNA | |
| SCHEMBL27166269 | 0.93 | SIGMAR1 (0.61) | SIGMAR1HRH2LMNA | |
| SCHEMBL27166236 | 0.92 | SIGMAR1 (0.62) | SIGMAR1HRH2LMNA | |
| SCHEMBL27166289 | 0.89 | SIGMAR1 (0.66) | SIGMAR1HRH2 | |
| SCHEMBL27166226 | 0.87 | SIGMAR1 (0.69) | SIGMAR1HRH2LMNA | |
| SCHEMBL27166277 | 0.84 | APP (0.45) | SIGMAR1HRH2DRD4 | |
| SCHEMBL27268645 | 0.84 | APP (0.45) | SIGMAR1HRH2DRD4 | |
| SCHEMBL27166296 | 0.84 | APP (0.45) | SIGMAR1HRH2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077069-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AG (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-4584251-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4583925-A1 | COMBINATIONS OF CONTRAST AGENTS | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052573-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052573-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052549-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052549-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335840-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4335461-A1 | COMBINATIONS OF CONTRAST AGENTS | Bayer AG (DE) | 2024-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077069-A1 | COMBINATIONS OF CONTRAST AGENTS | GBA1, GBA3, GLS2 | SIGMAR1 722/4885HRH2 1184/4885LMNA 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.